Patient-Based Bioequivalence Studies
When a molecule is too toxic to give a healthy volunteer, the study moves to patients already on therapy. We design and run patient-based BE studies through a pan-India investigator and site network.
Coverage
Execution
Site Network
Facility
What Is a Patient-Based Bioequivalence Study?
A patient-based bioequivalence study compares test and reference products in patients who are already receiving the drug as part of their treatment, rather than in healthy volunteers. The pharmacokinetic endpoints and statistics stay familiar — 90% confidence intervals for Cmax and AUC within 80.00–125.00% — but the population, the setting, and the logistics change completely.
The driver is ethics. Cytotoxic oncology drugs, and other molecules with genotoxic or otherwise unacceptable toxicity, cannot be dosed to healthy subjects who stand to gain no therapeutic benefit. Regulators including the US FDA, EMA, and CDSCO therefore direct BE studies for these products into patients — typically dosed within their scheduled treatment cycle, so the study adds sampling rather than extra exposure.
That shifts the challenge from the clinical pharmacology unit to the field: finding enough eligible patients under strict inclusion criteria, coordinating hospital sites and ethics committees, and moving PK samples reliably to a central laboratory. Our pan-India investigator and site network, coordinated from our DCGI-mandated centre in Pune, exists for exactly this kind of study.
Healthy-Volunteer BE vs Patient-Based BE
The statistics stay the same; everything around them changes.
| Aspect | Healthy-Volunteer BE | Patient-Based BE |
|---|---|---|
| Population | Screened healthy adults | Patients already receiving the drug as standard of care |
| When used | Default for most small-molecule generics | Cytotoxic oncology drugs and molecules too toxic for healthy subjects |
| Design | Single-dose, two-period crossover after washout | Crossover across treatment cycles, or steady-state and parallel designs when washout is not clinically acceptable |
| Setting | Confined clinical pharmacology unit | Hospital and oncology sites, sampled during scheduled therapy |
| Recruitment | Volunteer screening at one centre | Multi-site enrolment under strict inclusion and exclusion criteria |
| Acceptance criteria | 90% CI of Cmax & AUC within 80.00–125.00% | Identical — 90% CI of Cmax & AUC within 80.00–125.00% |
BE Studies Run Where the Patients Are
Patient BE succeeds or fails on recruitment and logistics. We enrol through a pan-India investigator and site network with Phase I–IV coverage, coordinate ethics approvals site by site, and route every PK sample to the LC-MS/MS laboratory at our 17,000 sq ft centre in Pune — one method, one lab, every site.
Patient BE Study Process
- 01
Feasibility & Site Mapping
Indication, eligible patient pool, and site shortlist assessed before the protocol is written — recruitment realism comes first.
- 02
Protocol & Ethics
A design that fits the treatment cycle, submitted to the relevant ethics committees for every participating site.
- 03
Enrolment Across Sites
Coordinated multi-site recruitment under strict criteria, with investigators dosing within standard-of-care schedules.
- 04
In-Cycle PK Sampling
Timed sampling around scheduled administrations and cold-chain transfer of samples to our central bioanalytical laboratory.
- 05
Bioanalysis, Statistics & Report
LC-MS/MS analysis on a single validated method, BE statistics, and a submission-ready clinical study report.
Why Sponsors Choose Us for Patient BE Studies
- Pan-India investigator and site network with Phase I–IV coverage
- DCGI-mandated, ANVISA-approved coordinating facility in Pune
- Recruitment feasibility assessed honestly before protocol commitment
- Single central LC-MS/MS laboratory for every study site
- Designs that respect treatment cycles — added sampling, not added exposure
- ICH-GCP E6 (R3) compliant conduct and oversight
Patient BE Studies — Frequently Asked Questions
1. Why are bioequivalence studies for cytotoxic drugs conducted in patients?
2. Which drugs require patient-based BE studies?
3. How is a BE study designed around treatment cycles?
4. Are the acceptance criteria different for patient BE studies?
5. How long does a patient-based bioequivalence study take?
6. Can a patient BE study support US FDA or EMA submissions?
More BA/BE Studies Services
Every study type under one roof — explore the rest of our ba/be studies capabilities.
Pilot BE Studies
Small, fast studies that measure formulation variability before you commit to a pivotal trial.
Fed & Fasting BE
Food-effect and fed BE studies that show your product performs against the reference in both dosing states.
Biosimilar PK Studies
Comparative pharmacokinetic similarity studies for biosimilars, backed by large-molecule LC-MS/MS.
Population BE
Designs and statistics for when average bioequivalence alone cannot answer the prescribability question.
Postmenopausal Studies
Special-population BA/BE studies in postmenopausal women for hormone and women’s-health products.
Transdermal Patch BE
TDS bioequivalence programs covering PK, adhesion, irritation, sensitization, and residual drug analysis.
Nasal Spray BE
Device-based BE combining in vitro performance testing with in vivo PK under a weight-of-evidence approach.
Bioanalytical Services
LC-MS/MS method development, ICH M10 validation, and study sample analysis — the lab behind every study.
Discuss Your Patient BE Studies Requirement
Share your molecule and target market — our scientific team responds with a study design, timeline, and detailed proposal within 24 business hours.